Accessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo
TELO’s Radiant Ascent: What’s Fueling the Rise?

Stock News

TELO’s Radiant Ascent: What’s Fueling the Rise?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 7/18/2025, 9:19 am ET 7/18/2025, 9:19 am ET | 5 min 5 min read
TELO’s Radiant Ascent: What’s Fueling the Rise? Thumbnail

In this article Last trade Feb, 09 6:52 PM

  • TELO-2.61%
    TELO - NASDAQTelomir Pharmaceuticals Inc.
    $1.12-0.03 (-2.61%)
    Volume:  78074
    Float:  20.89M
    $1.11Day Low/High$1.20

On Wednesday, Telomir Pharmaceuticals Inc.’s stock surged 152.07% following breakthrough trial results and strong FDA endorsements.

Candlestick Chart

Live Update At 09:18:42 EST: On Friday, July 18, 2025 Telomir Pharmaceuticals Inc. stock [NASDAQ: TELO] is trending up by 152.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Highlighting Financial Performance

In the fast-paced world of trading, it’s easy to get swept up in the excitement of trying to catch the next big opportunity. Beginners often feel pressured to jump on every trend, fearing they might miss out on potential profits. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This serves as a crucial reminder to traders to remain disciplined and patient. By focusing on honing their skills and sticking to their strategies, rather than impulsively chasing trends, traders can improve their chances of long-term success.

Telomir Pharmaceuticals is making waves with jaw-dropping scientific discoveries. Exciting, isn’t it? Our financial exploration unveils numbers that keep this small company afloat amidst its bustling research innovations. Though the revenue info hides within sheets of figures until now, expect less-than-amazing results with a disappearing cash flow of nearly $0.9M – a massive loss in layman’s terms.

The general and admin costs shot up, forcing Telomir to seek shelter with its, let’s say, skeletal assets gathered at $491,000. Stocks fluttered near $1.21 when scrutinized, from previous heights of above $1.7 earlier in June. Buckle up, as the price-to-book ratio wavers approximately -171.14, showcasing challenges on the road ahead.

Its earnings have been clouded by debts and unimpressive margins like the below-average quick ratio of 0.6 – a helmet to wear amidst tight turns. So, ladies and gentlemen, fasten your seatbelts!

Unraveling Telomir’s Mysteries

When June’s sun fueled scientific enthusiasm, the stock settings sparked narratives on hopes pinned to remarkable Telomir-1 findings. The social buzz crackled, weaving hopes across laboratories engaging uncharted territories. Despite gloomy financial clouds, the bright punch of scientific progress promises gleaming wisdom wrapped in potential possibilities for Telomir.

There, in the labs of Telomir, doors unlock secrets of aging cells that galvanize possibilities. With Telomir-1, the whispers of reversing tumor behavior echo loudly. But amid splendid promises, skeptics often murmur caution. Longtime supporters stand on shaky ground, pondering persistent shortfalls the balance sheet spreads starkly.

The tale of Telomir, though filled with overnight possibilities quickened by scientific gold, mandates patience, understanding, and sometimes, a brave heart willing to gamble with beliefs, almost like a twist of events in a suspense story.

More Breaking News

Narrating a New Chapter

Even as Telomir sends hopeful murmurings across corridors, the market drama unfolds—for better or for worse. An adventurous ride, almost like how daredevils dive into the unknown, Telomir’s journey curtails speculation and provides a road map of progressive ideals in the realm of pharmaceuticals.

In the spotlight today, venture between numbers and groundbreaking revelations as Telomir slowly writes its next page. Expect laughs and applause amid the shared promise to revitalize cell life, step by diligent step. Bear in mind, wise ones, riding this voyage holds more challenges, unbeknownst perhaps, hidden within the scrolls of whispers and numbers!

With a pinch of caution and a dash of excitement, we stride forward into the adrenaline-pumping world of Telomir. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” The question to embrace remains, are you ready to anchor your sails with Telomir as the tides of change roll in waves uncharted before, guided by scientific glory and shadowed uncertainties?

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

In this article (YTD Performance)

  • TELO-13.53%
    TELO - NASDAQTelomir Pharmaceuticals Inc.
    $1.12-0.03 (-2.61%)
    Volume:  78074
    Float:  20.89M
    $1.11Day Low/High$1.20

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Stop Guessing Trades. Follow Alerts Built for You.
Take the Quiz
notification icon
Subscribe to receive notifications